DRAIGON is a global project aiming to develop a novel diagnostic tool to tackle antimicrobial resistance (AMR) through the integration of genome sequencing and artificial intelligence (AI) technologies for patients infected with multi-drug resistant pathogens.

The consortium proposes to validate and demonstrate the clinical efficacy of a novel diagnostic test focusing on blood and joint infections at five hospitals across the globe (in the Netherlands, Austria, Albania and the United States). This diagnostic test will be easy to implement and may also function as an early detection system to prevent cross-border spread of pathogens. To guide the implementation of the tools developed in DRAIGON, an extensive health technology assessment (HTA) will be performed. This assessment will consider health-economic implications, patient outcomes, and social aspects.

The DRAIGON consortium is convinced that offering innovative genetic analysis of pathogens will improve clinical management for patients with infections, and monitoring of AMR. Thus, DRAIGON will directly enhance patient care and contribute to global AMR surveillance.